FeesSafety
Pluang+

Tether's Mining Development Kit gains support from 15 mining firms to unify Bitcoin mining tools.

Protocol Fundamentals
24 Oct 2026
Crypto Briefing
View Source
Bullish
Tether's Mining Development Kit gains support from 15 mining firms to unify Bitcoin mining tools.

Tether has announced that 15 mining operators, ASIC manufacturers, and mining pools have committed to integrating with its open-source Mining Development Kit (MDK). The MDK aims to solve compatibility issues in Bitcoin mining by providing a unified framework with a JavaScript SDK, React UI components, and a central orchestration kernel. Launched in April 2026, the MDK supports AI-powered automation and is expected to reach a stable version 1.0 by the end of 2026. This initiative builds on Tether's earlier MiningOS release and marks a significant step toward more interoperable and autonomous mining operations.

Tether's mining development kit and its recent industry support are noted here with Pluang market data as of Oct 24, 2026, 18:51 WIB. For readers following major cryptocurrencies, 6 out of 50 priced assets rose while 43 fell today. Notable movers include EGLD (MultiversX) at Rp60.783 with a 7.38% decline and 91% sell order activity, ONE (Harmony) at Rp24 with a 7.12% drop and 97% buy order activity, and COTI (COTI) at Rp198 down 6.11% with 84% sell order activity. The most notable figure is the 91% sell order activity on EGLD.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

Since August, U.S. spot Bitcoin exchange-traded funds (ETFs) have attracted about $6.4 billion in net inflows, significantly more than the roughly $1.5 billion in Bitcoin purchases by corporate treasuries. BlackRock’s IBIT ETF led with around $6 bill...

Market News
Bullish
4 hours ago
Aave (AAVE) price drops 5.29% to $140.12, dipping below key technical support levels.

Aave (AAVE) price drops 5.29% to $140.12, dipping below key technical support levels.

Aave (AAVE) experienced a 5.29% decline over 24 hours, falling to $140.12 as of early Saturday. This price slipped 51 cents below the lower Bollinger Band level of $140.63, a technical indicator noted on October 22. The chart also showed a relative s...

Technical Signals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App